SCHEMBL10176592

SCHEMBL10176592

Cc1ccc(C(=O)N2CCc3cc4c(cc3C2)nc2n4CCN(C3CCC3)CC2)cc1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM2B Q8NHM5 1/20 0.44
KDM4E B2RXH2 3/20 0.41
ALDH1A1 P00352 3/20 0.41
MAPT P10636 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
HRH3 Q9Y5N1 3/20 0.40
LMNA P02545 2/20 0.40
TP53 P04637 2/20 0.40
GAA P10253 1/20 0.40
PDE4B Q07343 6/20 0.39
PDE4D Q08499 4/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
L3MBTL3 Q96JM7 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
SYK P43405 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10176594 1.00 KDM2B (0.44) KDM2BKDM4EALDH1A1MAPTSMN1; SMN2
SCHEMBL421284 0.89 HRH3 (0.41) KDM2BKDM4EALDH1A1MAPTSMN1; SMN2
SCHEMBL421093 0.89 HRH3 (0.41) KDM2BKDM4EALDH1A1MAPTSMN1; SMN2
SCHEMBL417545 0.86 MAPT (0.46) KDM4EALDH1A1MAPTSMN1; SMN2NPC1
SCHEMBL418878 0.86 MAPT (0.46) KDM4EALDH1A1MAPTSMN1; SMN2NPC1
SCHEMBL420293 0.83 KEAP1 (0.41) KDM4EALDH1A1MAPTSMN1; SMN2NPC1
SCHEMBL1345020 0.83 KEAP1 (0.41) KDM4EALDH1A1MAPTSMN1; SMN2NPC1
SCHEMBL422810 0.81 ESR1 (0.42) KDM4EALDH1A1MAPTSMN1; SMN2NPC1
SCHEMBL10176749 0.81 KDM2B (0.47) KDM2BKDM4EALDH1A1MAPTSMN1; SMN2
SCHEMBL10176755 0.79 PROKR1 (0.48) KDM2BKDM4EALDH1A1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8404670-B2 Histamine H3 inverse agonists and antagonists and methods of use thereof SUNOVION PHARMACEUTICALS INC. (US) 2013-03-26 US disclosed
US-20120022050-A1 HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. 2012-01-26 US disclosed
US-8063032-B2 Histamine H3 inverse agonists and antagonists and methods of use thereof SUNOVION PHARMACEUTICALS INC. (US) 2011-11-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022050-A1 HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF HRH3, HRH4, HRH2 KDM2B 1707/4885KDM4E 1889/4885ALDH1A1 2598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.